News coverage about La Jolla Pharmaceutical (NASDAQ:LJPC) has been trending positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. La Jolla Pharmaceutical earned a media sentiment score of 0.30 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 47.3399696253511 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of brokerages have weighed in on LJPC. Zacks Investment Research downgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Jefferies Group LLC restated a “buy” rating and issued a $40.00 price objective on shares of La Jolla Pharmaceutical in a research note on Tuesday, October 3rd. J P Morgan Chase & Co initiated coverage on shares of La Jolla Pharmaceutical in a research note on Wednesday, August 30th. They issued an “overweight” rating and a $36.00 price objective for the company. BidaskClub upgraded shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Finally, Chardan Capital restated a “buy” rating and issued a $85.00 price objective on shares of La Jolla Pharmaceutical in a research note on Tuesday, August 8th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $52.00.
Shares of La Jolla Pharmaceutical (LJPC) opened at $34.70 on Wednesday. La Jolla Pharmaceutical has a 1 year low of $16.41 and a 1 year high of $39.28.
La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.05. analysts expect that La Jolla Pharmaceutical will post -4.93 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://weekherald.com/2017/11/15/la-jolla-pharmaceutical-ljpc-receiving-positive-news-coverage-report-finds.html.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with MarketBeat.com's FREE daily email newsletter.